A late clinical-stage
biopharmaceutical company
Stock code: XXXX.HK
We engage transparently with the financial community
on our science-driven strategy, performance,
and long-term outlook.
Latest News
-
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
Read more -
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
Read more -
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
Read more
